SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Herantis Pharma Extends HER-096 Phase 2 Placebo-Controlled Treatment to Nine Months

Herantis Pharma is extending the placebo-controlled treatment period in the HER-096 Phase 2 study to nine months.

Related stories